Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.
| Revenue (Most Recent Fiscal Year) | $76.99M |
| Net Income (Most Recent Fiscal Year) | $-174.57M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 8.11 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.51 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -119.54% |
| Net Margin (Trailing 12 Months) | -119.54% |
| Return on Equity (Trailing 12 Months) | -47.86% |
| Return on Assets (Trailing 12 Months) | -26.78% |
| Current Ratio (Most Recent Fiscal Quarter) | 7.87 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.97 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.44 |
| Inventory Turnover (Trailing 12 Months) | 0.08 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.42 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.03 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.27 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.21 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 636.92M |
| Free Float | 589.66M |
| Market Capitalization | $942.64M |
| Average Volume (Last 20 Days) | 11.80M |
| Beta (Past 60 Months) | 0.76 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.42% |
| Percentage Held By Institutions (Latest 13F Reports) | 73.71% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |